ERErling W. Rud

Erling W. Rud

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erling W. Rud has a total of 206 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Brain Microbial Populations in HIV/AIDS: α-Proteobacteria Predominate Independent of Host Immune Status

    by William G. Branton, Kristofor K. Ellestad, Ferdinand Maingat, B. Matt Wheatley, Erling Rud, René L. Warren, Robert A. Holt, Michael G. Surette, Christopher Power

    The brain is assumed to be a sterile organ in the absence of disease although the impact of immune disruption is uncertain in terms of brain microbial diversity or quantity. To investigate microbial diversity and quantity in the brain, the profile of infectious agents was examined in pathologically normal and abnormal brains from persons with HIV/AIDS [HIV] (n = 12), other disease controls [ODC] (n = 14) and in cerebral surgical resections for epilepsy [SURG] (n = 6). Deep sequencing of cerebral white matter-derived RNA from the HIV (n = 4) and ODC (n = 4) patients and SURG (n = 2) groups revealed bacterially-encoded 16 s RNA sequences in all brain specimens with α-proteobacteria representing over 70% of bacterial sequences while the other 30% of bacterial classes varied widely. Bacterial rRNA was detected in white matter glial cells by in situ hybridization and peptidoglycan immunoreactivity was also localized principally in glia in human brains. Analyses of amplified bacterial 16 s rRNA sequences disclosed that Proteobacteria was the principal bacterial phylum in all human brain samples with similar bacterial rRNA quantities in HIV and ODC groups despite increased host neuroimmune responses in the HIV group. Exogenous viruses including bacteriophage and human herpes viruses-4, -5 and -6 were detected variably in autopsied brains from both clinical groups. Brains from SIV- and SHIV-infected macaques displayed a profile of bacterial phyla also dominated by Proteobacteria but bacterial sequences were not detected in experimentally FIV-infected cat or RAG1−/− mouse brains. Intracerebral implantation of human brain homogenates into RAG1−/− mice revealed a preponderance of α-proteobacteria 16 s RNA sequences in the brains of recipient mice at 7 weeks post-implantation, which was abrogated by prior heat-treatment of the brain homogenate. Thus, α-proteobacteria represented the major bacterial component of the primate brain’s microbiome regardless of underlying immune status, which could be transferred into naïve hosts leading to microbial persistence in the brain.


  • Evidence of recombination producing allelic diversity in MHC class I Mafa-B and -A alleles in cynomolgus macaques

    by D. Orysiuk, J. Lawrence, T. Prashar, L. Spangelo, R. Pilon, J. Fournier, E. Rud, P. Sandstrom, F. A. Plummer, M. Luo


  • Identification of 23 novel MHC class I alleles in cynomolgus macaques of Philippine and Philippine/Mauritius origins

    by J. Lawrence, D. Orysiuk, T. Prashar, R. Pilon, J. Fournier, E. Rud, P. Sandstrom, F. A. Plummer, M. Luo

    We report here novel Mafa‐A, ‐AG and ‐B alleles identified in two groups of cynomolgus macaques.


  • Persistence of restricted CD4 T cell expansions in SIV-infected macaques resistant to SHIV89.6P superinfection

    by M.-D. Salha, R. Cheynier, R. Halwani, H. McGrath, T.Y. Langaee, B. Yassine Diab, J. Fournier, M. Parenteau, J. Edgar, D. Ko, et al.


  • Open Access

    Gene Expression Profiling of Host Response in Models of Acute HIV Infection

    by Steven E Bosinger, Karoline A Hosiawa, Mark J. Cameron, Desmond Persad, Longsi Ran, Luoling Xu, Mohamed R. Boulassel, Monique Parenteau, Jocelyn Fournier, Erling W. Rud, et al.

    HIV infection is characterized by a host response composed of adaptive and innate immunity that partially limits viral replication; however, it ultimately fails in eradicating the virus. To model host gene expression during acute HIV infection, we infected cynomolgus macaques with the SIV/HIV-1 chimeric virus, SHIV89.6P, and profiled gene expression in peripheral blood over a 5-wk period using a high density cDNA microarray. We demonstrate that viral challenge induced a widespread suppression of genes regulating innate immunity, including the LPS receptors, CD14 and TLR4. An overexpression of 16 IFN-stimulated genes was also observed in response to infection; however, it did not correlate with control over viral titers. A statistical analysis of the dataset identified 10 genes regulating apoptosis with differential expression during the first 2 wk of infection (p < 0.004). Quantitative real-time PCR verified transcriptional increases in IFN-α-inducible genes and decreases in genes regulating innate immunity. Therefore, the persistence of high viral loads despite an extensive IFN response suggests that HIV can resist in vivo IFN treatment despite published reports of in vitro efficacy. The transcriptional suppression of genes regulating innate immunity may allow HIV to evade acute host responses and establish a chronic infection and may reduce innate host defense against opportunistic infections.


  • Open Access

    Multispecific Vaccine-Induced Mucosal Cytotoxic TLymphocytes Reduce Acute-Phase Viral Replication but Fail inLong-Term Control of Simian Immunodeficiency VirusSIVmac239

    by Thorsten U. Vogel, Matthew R. Reynolds, Deborah H. Fuller, Kathy Vielhuber, Tim Shipley, James T. Fuller, Kevin J. Kunstman, Gerd Sutter, Marta L. Marthas, Volker Erfle, et al.

    Given the current difficulties generating vaccine-induced neutralizing antibodies to human immunodeficiency virus (HIV), the focus of the vaccine community has shifted toward creating cytotoxic-T-lymphocyte (CTL)-based vaccines. Recent reports of CTL-based vaccine trials in macaques challenged with simian/human immunodeficiency virus SHIV-89.6P have supported the notion that such vaccines can ameliorate the course of disease. However, almost all of these studies included Env as an immunogen and since SHIV-89.6P is sensitive to neutralizing antibodies it is difficult to determine the mechanism(s) of protection. Consequently, SHIV-89.6P challenge of macaques may be a poor model for determining vaccine efficacy in humans. To ascertain the effect of vaccine-induced multispecific mucosal CTL, in the absence of Env-specific antibody, on the control of an immunodeficiency virus challenge, we vaccinated Mamu-A*01+macaques with constructs encoding a combination of CTL epitopes and full-length proteins (Tat, Rev, and Nef) by using a DNA prime/recombinant modified vaccinia virus Ankara (rMVA) boost regimen. The vaccination induced virus-specific CTL and CD4+helper T lymphocytes with CTL frequencies as high as 20,000/million peripheral blood mononuclear cells. The final rMVA vaccination, delivered intravenously, engendered long-lived mucosal CTL. At 16 weeks after the final rMVA vaccination, the vaccinees and naive, Mamu-A*01+controls were challenged intrarectally with SIVmac239. Massive early anamnestic cellular immune responses controlled acute-phase viral replication; however, the three vaccinees were unable to control virus replication in the chronic phase. The present study suggests that multispecific mucosal CTL, in the absence of neutralizing antibodies, can achieve a modicum of control over early viral replication but are unable to control chronic-phase viral replication after a high-dose mucosal challenge with a pathogenic simian immunodeficiency virus.


  • Cross-species retroviral transmission from macaques to human beings

    by James I Brooks, Erling W Rud, Richard G Pilon, Jonathan M Smith, William M Switzer, Paul A Sandstrom


  • Xenoinfection of nonhuman primates by feline immunodeficiency virus

    by James B Johnston, Merle E Olson, Erling W Rud, Christopher Power


  • Mechanisms of protection induced by live attenuated simian immunodeficiency virus

    by Peter Silvera, Alison Wade‐Evans, Erling Rud, Robin Hull, Kirsty Silvera, Rebecca Sangster, Neil Almond, Jim Stott

    In this study, we investigated whether a type of retroviral interference might be one mechanism that mediates the powerful protection induced by live attenuated SIVC8. Our results show that retroviral interference could be demonstrated between SIV and SHIV‐HXBc2 in human T‐cell lines chronically infected with either SIVC8 or SIVJ5. Lymphocytes from macaques infected with live attenuated SIVC8 were significantly less sensitive (Pin vitro infection by virulent SIVJ5 and SHIV‐HXBc2 than were lymphocytes from naïve controls. However, this significant difference in the sensitivity of lymphocytes to virus infection was not observed for more efficiently replicating viruses such as SHIVSF33 and SIVsm3. Virus growth was significantly enhanced (Pin vitro and in vivo. We found that levels of the β‐chemokines regulated upon activation, normal T‐cell expressed and secreted, macrophage inflammatory protein‐1α and macrophage inflammatory protein‐1β did not correlate with inhibition of virus replication. Taken together, our findings do not support the hypothesis that retroviral interference is the mechanism by which live attenuated SIVC8 induces protection.